Original Article
Rad F, Nik-Khoo B, Yaghmaee R, Gharibi F. Terbinafin 1% Cream and Ketoconazole 2% Cream in the Treatment of Pityriasis Versicolor:
A randomized comparative clinical trial. Pak J Med Sci 2014;30(6):1273-1276.
doi: http://dx.doi.org/10.12669/pjms.306.5509
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Pityriasis versicolor (tinea versicolor) is a common
mild infection of the skin which is caused by the
lipophilic yeast Malassezia furfur.1 Colonization of
the skin by this organism more frequently occurs
1.
2.
3.
4.
1-4:
Correspondence:
*
*
www.pjms.com.pk 1273
www.pjms.com.pk
Group 1
Group 2
p
(Terbinafine) (ketoconazole)
N(%)
N(%)
13(27.1)
12(28.6)
0.4
18(37.5) 17(40.5)
13(27.1) 11(26.2)
4(8.3)
2(4.8)
28(66.7)
20(33.3)
28(58.3)
14(41.7)
0.41
23(47.9)
26(61.9)
0.64
5(10.4)
12(25.0)
8(16.7)
4(9.5)
7(16.7)
5(11.9)
30(58.8)
9(17.7)
7(13.7)
5(9.8)
28(58.3)
8(7/16)
6(12.5)
6(12.5)
0.97
Table-II: Comparison of the therapeutic effects of terbinafine cream with ketoconazole cream
at the end of the 2nd, 4th and 8th week of study.
Time
Cure
Group 1 (Terbinafine)
N(%)
N(%)
Cured
Not cured
Cured
Not cured
Cured
Not cured
35(72.1)
13(27.9)
39(81.2)
9(18.8)
34(70.8)
14(29.2)
27(64.3)
15(35.7)
29(69.0)
13(31.0)
26(61.9)
16(38.1)
Group 2 (ketoconazole)
p
0.38
0.8
0.37
E-Flowchart
Pak J Med Sci 2014 Vol. 30 No. 6
www.pjms.com.pk 1275
REFERENCES
1.
www.pjms.com.pk
6. Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. Vol II, 2nd.
Philadelphia: Mosby. 2008:942.
7. Terragni L, Lasagni A, Oriani A. Pityriasis versicolor of the face.
Mycoses. 1991;34:345-347.
8. Terragni L, Lasagni A, Oriani A, Gelmetti C. Pityriasis versicolor
in the pediatric age. Pediatr Dermatol. 1991;8:9-12.
9. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF,
Hordinsky MK, et al. Guidelines of care for superficial mycotic
infections of the skin: Pityriasis (tinea) versicolor. Guidelines/
Outcomes Committee. American Academy of Dermatology. J
Am Acad Dermatol. 1996;34(2 Pt 1):287-289.
10. Rad F, Aala F, Reshadmanesh N, Yghmaie R. Randomized
comparative clinical trial of Artemisia sieberi 5% lotion and
clotrimazole 1% lotion for the treatment of pityriasis versicolor.
Indian J Dermatol. 2008;53(3):115-118. doi: 10.4103/00195154.43209.
11. Aste N, Pau M, Pinna AL, Colombo MD, Biggio P. Clinical
efficacy and tolerability of terbinafine in patients with pityriasis
versicolor. Mycoses. 1991;34:353-357.
12. Nimura K, Niwano Y, Ishiduka S. Comparison of In Vitro
antifungal activities of topical antimycotics launched in 1990s in
Japan. Int J Antimicrobial Agent. 2001;18:173-178. doi:10.1016/
S0924-8579(01)00365
13. Hay RJ. Lamizil the evidence. Science and technology 1st Edition,
New York. The Parthenon publishing group international
publisher in medicine, 2001; 7-9, 66, 75-84.
14. Savin R, Eisen D, Fradin MS, Lebwohl M. Tinea versicolor
treated with terbinafine 1% solution. Int J Dermatol.
1999;38(11):863-865.
15. Savin RC, Horwitz SN, Double-blind comparison of 2%
ketoconazole cream and placebo in the treatment of tinea
versicolor. J Am Acad Dermatol. 1986;15(3):500-503.
16. Lange DS, Richards HM, Guarnieri J, Humeniuk JM, Savin
RC, Reyes BA, et al. Ketoconazole 2% shampoo in the
treatment of tinea versicolor: a multicenter, randomized,
double-blind, placebo- controlled trial. J Am Acad Dermatol.
1998;39(6):944-950.
17. Rekacewicz I, Guillaume JC, Benkhraba F, Archimbaud A,
Baspeyras M, Boitier F, et al. Adouble-blind placebo controlled
study of a 2 percent foaming lotion of ketoconazloe in a single
application in the treatment of pityriasis versicolor. Ann
Dermatol Venereol. 1990;117(10):709-711.
18. Di-Fonzo EM, Martini P, Mazzatenta C, Lotti L, Alvino
S. Comparative efficacy and tolerability of ketomousse
(ketoconazole foam 1%) and ketoconazole cream 2% in the
treatment of pityriasis versicolor: Results of a prospective,
multicenter, randomized study. Mycoses. 2008;51(6):532-535.
doi: 10.1111/j.1439-0507.2008.01508.
19. Muzaffar F, Ejaz A, Mahmood Kh. Determination of cost
effective topical therapy for pityriasis versicolor. J Pak Assoc
Drema. 2008;18(3):159-164.
20. Bhogal CS, Singal A, Baruah MC. Comparative efficacy of
ketoconazole and fluconazole in the treatment of pityriasis
versicolor: a one year follow-up study. J Dermatol.
2001;28(10):535-539.
21. Rigopoulos D, Gregoriou S, Kontochristopoulos G, Ifantides A,
katsambas A. Flutrimazole shampoo 1% versus ketoconazole
shampoo 2% in the treatment of pityriasis versicolor. A
randomized double blind comparative trial. Mycoses.
2007;50(3):193-195. doi:10.1111/j.1439-0507.2006.01352.
22. Faergemann J, Hersle K, Nordin P. Pityriasis versicolor:
clinical experience with lamisil cream and lamisil dermgel.
Dermatology. 1997;194(Suppl 1):19-21.
23. Vermeer B J, Staats CC. The efficacy of a topical application of
terbinafine 1% solution in subjects with pityriasis versicolor:
a placebo-controlled study. Dermatology. 1997;194(Suppl
1):22-24.
24. Chopra V, Jain VK. Comparative study of topical terbinafine and
topical ketoconazole in pityriasis versicolor. Indian J Dermatol
Venerol Leprol. 2000;66(6):299-300.